DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice
Launched by IMED19 · Dec 11, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial aims to study patients who have certain medical conditions, such as liver dysfunction, thyroid issues, heart disease, and intestinal problems, to better understand and improve the quality of their healthcare. The researchers want to gather information about these patients from a large internal medicine practice, identify those at higher risk for complications, and use imaging test results to help manage their care more effectively. By doing this, they hope to find areas where treatment can be improved based on real-world patient data.
To participate in this study, individuals must be over 18 years old and diagnosed with one of the listed conditions, have recent lab results (within the last 3 months), and have undergone imaging tests at the practice. This study will take place during regular patient visits, so those who join can expect to share their health information in a routine setting. It’s important to note that this trial is not yet recruiting participants, but it aims to provide valuable insights into how to enhance care for patients with these chronic conditions.
Gender
ALL
Eligibility criteria
- • 1. Female or male patients aged above 18 years diagnosed with chronic liver disease, undergo on-site endoscopy, suffer from atherosclerosis, heart failure, are diagnosed with abnormal serum thyroid-stimulating hormone (TSH) levels, either overt or latent hypo- or hyperthyroidism, or are diagnosed with solitary or multiple thyroid nodules.
- • 2. Routine laboratory results available within the last 3 months.
- • 3. Available imaging data within the last 3 months performed on site.
About Imed19
imed19 is a forward-thinking clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study designs and rigorous methodologies. Specializing in a diverse range of therapeutic areas, imed19 collaborates with healthcare professionals and institutions to facilitate the development of groundbreaking treatments. With a commitment to ethical standards and regulatory compliance, imed19 prioritizes patient safety and data integrity, ensuring that every trial contributes valuable insights to the scientific community and enhances the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported